Autopsy report · NCT02589145
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Cause of deathSlow enrollment
“Closed due to very slow accrual”
Life of this trial
- Registered 8 months before it started.
- Ran for about 2 years 10 months before it stopped.
- 8 participants enrolled.
- Results were posted on the registry 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Lymphoma
- Interventions
- Lenalidomide; Vorinostat; Gemcitabine; Busulfan; Melphalan; Rituximab
- Participants
- 8
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
“Closed early due to slow accrual” - Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
“Closed due to low accrual” - Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
“Slow accrual; closed by funder” - S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
“Permanently Closed Due to Poor Accrual” - Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
“Closed prematurely because the accrual was not achieved”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.